CANCER, VASCULAR DISEASE and low-dose ASPIRIN

Fifty years of research by The Welsh Aspirin Group

1974 – 2024

For five decades, the Welsh Aspirin Group has explored the potential of low-dose aspirin in reducing deaths from vascular disease and improving outcomes in cancer treatment. Building on landmark trials from the 1970s, our research spans randomised studies, observational data, biological mechanisms, and global health implications.

This report presents compelling evidence that aspirin may:

• Reduce cancer mortality by ~20% across multiple cancer types
• Delay metastatic spread and improve long-term survival
• Lower vascular complications in cancer patients
• Offer a low-cost, globally accessible treatment option

We also address safety concerns, especially bleeding risks, and highlight the importance of informed patient-doctor discussions. With mounting evidence and public support, we believe it’s time to share these findings widely – with clinicians, researchers, policymakers, and patients.

Explore the data, the debate, and the potential of aspirin in cancer care.

50-years-of-research